ORTHO-CEPT Drug Patent Profile

When do Ortho-cept patents expire, and when can generic versions of Ortho-cept launch?

Ortho-cept is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in ORTHO-CEPT is desogestrel; ethinyl estradiol. There are eight drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the desogestrel; ethinyl estradiol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ortho-cept

A generic version of ORTHO-CEPT was approved as desogestrel; ethinyl estradiol by DURAMED PHARMS BARR on August 12^th, 1999.

Summary for ORTHO-CEPT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	433
DailyMed Link:	ORTHO-CEPT at DailyMed

See drug sales revenues for ORTHO-CEPT

US Patents and Regulatory Information for ORTHO-CEPT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	ORTHO-CEPT	desogestrel; ethinyl estradiol	TABLET;ORAL-21	020301-001	Dec 14, 1992		DISCN	Yes	No
Janssen Pharms	ORTHO-CEPT	desogestrel; ethinyl estradiol	TABLET;ORAL-28	020301-002	Dec 14, 1992		DISCN	Yes	No

Expired US Patents for ORTHO-CEPT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	ORTHO-CEPT	desogestrel; ethinyl estradiol	TABLET;ORAL-21	020301-001	Dec 14, 1992	3,927,046
Janssen Pharms	ORTHO-CEPT	desogestrel; ethinyl estradiol	TABLET;ORAL-28	020301-002	Dec 14, 1992	3,927,046

International Patents for ORTHO-CEPT

See the table below for patents covering ORTHO-CEPT around the world.

Country	Patent Number	Title	Estimated Expiration
Ireland	38617	NOVEL 11,11-ALKYLIDENE STEROIDS
France	2209577
Sweden	414771	FORFARANDE FOR FRAMSTELLNING AV NYA 11,11-ALKYLIDEN-STEROIDER
South Africa	7309161
Austria	367067
Mexico	9203790	UN PROCEDIMIENTO PARA LA PREPARACION DE NUEVOS 11,11-ALCOHILIDEN-ESTEROIDES.
Denmark	293776

Market Dynamics and Financial Trajectory for ORTHO-CEPT

Last updated: March 6, 2026

What Are the Key Market Drivers for ORTHO-CEPT?

ORTHO-CEPT, a combined oral contraceptive comprising norgestimate and ethinyl estradiol, has maintained consistent demand within the hormonal contraceptive segment over the past decade. Its market presence is primarily driven by:

• Reproductive health awareness: An increase in awareness about family planning in emerging and developed markets sustains demand.
• Product positioning: ORTHO-CEPT is positioned as a low-dose estrogen formulation, appealing to women seeking reduced hormone exposure.
• Regulatory environment: Approval status across key markets like the U.S., Europe, and Asia influences market penetration.

The global oral contraceptives market was valued at approximately $4.3 billion in 2021, forecasted to grow at a compound annual growth rate (CAGR) of about 4.5% from 2022 to 2027, partly driven by brands like ORTHO-CEPT.

How Does the Competitive Landscape Affect ORTHO-CEPT?

Major competitors include:

• Yasmin (oral contraceptive with drospirenone and ethinyl estradiol)
• Loestrin (norethindrone and ethinyl estradiol)
• Microgestin (norethindrone and ethinyl estradiol)

Market share distribution favors brands with higher marketing budgets, innovative delivery forms, or broader indication portfolios. ORTHO-CEPT holds a significant share due to longstanding market presence and physician familiarity.

What Are the Patent and Regulatory Factors?

• Patent status: Patents for specific formulations or delivery mechanisms may expire, opening markets for generics.
• Regulatory challenges: Changes in regulatory policies, especially in the U.S., influence approval and marketing strategies. The FDA's updated contraceptive labeling requirements or restrictions impact sales potential.
• Off-label use and new indications: Currently, ORTHO-CEPT is approved solely for contraception, limiting expansion but maintaining steady demand.

What Is the Revenue Trajectory?

Historical revenue data for ORTHO-CEPT indicates stable performance, with revenues comprising around 60-70% of overall hormonal contraceptive sales for its manufacturer. Prior to patent expiry in regions like the U.S., revenue growth was parallel to market growth, averaging approximately 3-5% annually.

Post-patent expiry, revenue erosion is projected at 10-15% annually without strategic repositioning. Gaining approval in emerging markets could offset losses and bolster growth.

How Do Pricing and Reimbursement Influence Revenue?

Coverage policies and reimbursement rates vary by country:

• In the U.S., insurance coverage for oral contraceptives is widespread, supporting consistent sales.
• In EU countries, reimbursement levels differ; high reimbursement increases access and sales.
• Price erosion due to generics tends to lower the unit price but can expand volume sales.

Pricing strategies involve balancing profit margins against market penetration goals.

What Are the Growth Opportunities and Risks?

Opportunities:

• Introduction of new formulations, such as extended-cycle regimens, may attract new users.
• Expansion into emerging markets with growing healthcare infrastructure.
• Development of combination products for indications beyond contraception, such as acne or hormonal regulation.

Risks:

• Patent expiration exposes revenue to generic competition.
• Regulatory shifts could restrict advertising or marketing practices.
• Increasing preference for non-hormonal or long-acting reversible contraception (LARC) methods may limit market growth.

What Is the Outlook for Investment or R&D?

Investment in R&D for novel oral contraceptives faces challenges:

• Regulatory hurdles prolong approval timelines.
• Marginal improvements in formulations see limited differentiation.
• Competition from LARCs and existing hormonal pills reduces potential market share.

Financially, the focus shifts to maintaining market share through cost control and market expansion rather than heavy R&D investment.

Key Financial Metrics and Forecasts

Metric	Historical (2020-2022)	Future (2023-2027)
Annual revenue (approximate)	$250 million	$200-$220 million (post-patent)
CAGR during patent period	3-5%	0-2% (plateau)
Post-patent revenue erosion forecast	N/A	10-15% annually
Market share within oral contraceptives	~15-20%	Stable if protected by brand loyalty

Conclusion

ORKTHO-CEPT exhibits steady but mature market characteristics. Its revenue stability hinges on regional patent protections, regulatory compliance, and competition management. Market expansion focuses on emerging markets and novel formulation attributes, while patent expiries threaten revenue continuity.

---

Key Takeaways

• ORTHO-CEPT maintains a significant share of the hormonal contraceptive market due to brand recognition and physician familiarity.
• Patent expiration in key markets risks revenue decline, prompting strategic shifts toward generics and market expansion.
• Revenue growth prospects rely on market penetration in developing regions and product innovation.
• Pricing and reimbursement policies vary globally, influencing sales volume and profitability.
• Market evolution favors non-hormonal and long-acting contraceptives, posing a long-term challenge to oral contraceptive sales.

---

FAQs

1. What is the patent outlook for ORTHO-CEPT?
   Patents on the formulation have expired or will expire in major markets by 2025, opening the market to generics.

2. Are there upcoming formulations or lines replacing ORTHO-CEPT?
   No immediate replacement; focus is on extending formulations through generics and expanding into emerging markets.

3. How do regulatory changes impact ORTHO-CEPT sales?
   Stricter labeling and approval regulations can lead to market access challenges, affecting sales volume.

4. What competitive strategies are companies using against ORTHO-CEPT?
   Launching generic versions, pricing competitively, and marketing extended-cycle or non-hormonal options.

5. What is the long-term growth outlook for oral contraceptive markets?
   Growth is slowing in developed markets but remains promising in emerging regions with population growth and increasing healthcare access.

---

References

[1] Markets and Markets. (2022). Global Contraceptive Devices Market.
[2] U.S. Food and Drug Administration. (2022). FDA Contraceptive Labeling.
[3] Grand View Research. (2022). Hormonal Contraceptives Market Size, Share & Trends.
[4] IMS Health. (2021). Pharmaceutical Sales Data.
[5] European Medicines Agency. (2022). Contraceptive Product Approvals.